The development of innovative pharmaceuticals targeting refractory mental health conditions has stagnated for decades. In recent years, ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly ...

Tylah Tully chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham about the company's recent ...

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

Fecal microbiota transplants (FMT) have been touted as a potential treatment for a variety of conditions, from inflammatory ...

It’s finally beach weather across the US. Are you applying enough sunscreen? - As the weather heats up and Americans head ...

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

A good drug should cure without harming. A lot depends, however, not so much on the therapeutic substance itself, as on the ...